全文获取类型
收费全文 | 181843篇 |
免费 | 16563篇 |
国内免费 | 10811篇 |
专业分类
耳鼻咽喉 | 1703篇 |
儿科学 | 2713篇 |
妇产科学 | 1174篇 |
基础医学 | 14559篇 |
口腔科学 | 3406篇 |
临床医学 | 20914篇 |
内科学 | 21986篇 |
皮肤病学 | 1982篇 |
神经病学 | 6740篇 |
特种医学 | 7388篇 |
外国民族医学 | 25篇 |
外科学 | 19309篇 |
综合类 | 40872篇 |
现状与发展 | 47篇 |
一般理论 | 10篇 |
预防医学 | 18714篇 |
眼科学 | 2843篇 |
药学 | 20242篇 |
199篇 | |
中国医学 | 13129篇 |
肿瘤学 | 11262篇 |
出版年
2024年 | 693篇 |
2023年 | 2141篇 |
2022年 | 5338篇 |
2021年 | 7331篇 |
2020年 | 5874篇 |
2019年 | 4083篇 |
2018年 | 4349篇 |
2017年 | 5070篇 |
2016年 | 4561篇 |
2015年 | 7552篇 |
2014年 | 9737篇 |
2013年 | 11003篇 |
2012年 | 15864篇 |
2011年 | 17013篇 |
2010年 | 14486篇 |
2009年 | 12575篇 |
2008年 | 13719篇 |
2007年 | 13429篇 |
2006年 | 11843篇 |
2005年 | 10116篇 |
2004年 | 7386篇 |
2003年 | 6609篇 |
2002年 | 5431篇 |
2001年 | 3776篇 |
2000年 | 2917篇 |
1999年 | 1534篇 |
1998年 | 824篇 |
1997年 | 820篇 |
1996年 | 576篇 |
1995年 | 506篇 |
1994年 | 435篇 |
1993年 | 281篇 |
1992年 | 229篇 |
1991年 | 199篇 |
1990年 | 141篇 |
1989年 | 107篇 |
1988年 | 92篇 |
1987年 | 87篇 |
1986年 | 81篇 |
1985年 | 43篇 |
1984年 | 51篇 |
1983年 | 36篇 |
1982年 | 34篇 |
1981年 | 19篇 |
1980年 | 21篇 |
1978年 | 20篇 |
1975年 | 16篇 |
1973年 | 16篇 |
1972年 | 18篇 |
1957年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Kazunori Aizawa Takeshi Hanaoka Hiroki Kasai Kaoru Kogashi Setsuo Kumazaki Jun Koyama Hiroshi Tsutsui Yoshikazu Yazaki Noboru Watanabe Osamu Kinoshita Uichi Ikeda 《Hypertension research》2006,29(2):123-128
The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, has been reported to produce sustained pulmonary vasodilatation in patients with pulmonary hypertension (PH). Recently, vardenafil, a more potent and selective PDE-5 inhibitor than sildenafil, has been approved for the treatment of erectile dysfunction. However, the long-term effects of oral vardenafil in patients with PH are unknown. We studied five consecutive patients with PH; one with primary pulmonary hypertension, two with chronic pulmonary thromboembolism, one with Eisenmenger syndrome (ventricular septal defect) and one with secondary pulmonary hypertension after a ventricular septal defect closure operation. In an acute hemodynamic trial, vardenafil (5 mg) significantly decreased both the pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) with an increase in cardiac output. In a chronic hemodynamic trial, the maintenance dose of vardenafil (10 to 15 mg) for 3 months significantly decreased the PVR, but not the SVR, with a 20.7% reduction of the PVR/ SVR ratio. Plasma brain natriuretic peptide (BNP) levels were also significantly decreased after 3 months. This pilot study demonstrates that long-term oral vardenafil therapy may be a safe and effective treatment for patients with PH. 相似文献
3.
Jun Agata Nobuyuki Ura Hideaki Yoshida Yasuyuki Shinshi Haruki Sasaki Masaya Hyakkoku Shinya Taniguchi Kazuaki Shimamoto 《Hypertension research》2006,29(11):865-874
Angiotensin II receptor blockers (ARBs) are widely used for the treatment of hypertension. It is believed that treatment with an ARB increases the level of plasma angiotensin II (Ang II) because of a lack of negative feedback on renin activity. However, Ichikawa (Hypertens Res 2001; 24: 641-646) reported that long-term treatment of hypertensive patients with olmesartan resulted in a reduction in plasma Ang II level, though the mechanism was not determined. It has been reported that angiotensin 1-7 (Ang-(1-7)) potentiates the effect of bradykinin and acts as an angiotensin-converting enzyme (ACE) inhibitor. It is known that ACE2, which was discovered as a novel ACE-related carboxypeptidase in 2000, hydrolyzes Ang I to Ang-(1-9) and also Ang II to Ang-(1-7). It has recently been reported that olmesartan increases plasma Ang-(1-7) through an increase in ACE2 expression in rats with myocardial infarction. We hypothesized that over-expression of ACE2 may be related to a reduction in Ang II level and the cardioprotective effect of olmesartan. Administration of 0.5 mg/kg/day of olmesartan for 4 weeks to 12-week-old stroke-prone spontaneously hypertensive rats (SHRSP) significantly reduced blood pressure and left ventricular weight compared to those in SHRSP given a vehicle. Co-administration of olmesartan and (D-Ala7)-Ang-(1-7), a selective Ang-(1-7) antagonist, partially inhibited the effect of olmesartan on blood pressure and left ventricular weight. Interestingly, co-administration of (D-Ala7)-Ang-(1-7) with olmesartan significantly increased the plasma Ang II level (453.2+/-113.8 pg/ml) compared to olmesartan alone (144.9+/-27.0 pg/ml, p<0.05). Moreover, olmesartan significantly increased the cardiac ACE2 expression level compared to that in Wistar Kyoto rats and SHRSP treated with a vehicle. Olmesartan significantly improved cardiovascular remodeling and cardiac nitrite/ nitrate content, but co-administration of olmesartan and (D-Ala7)-Ang-(1-7) partially reversed this anti-remodeling effect and the increase in nitrite/nitrate. These findings suggest that olmesartan may exhibit an ACE inhibitory action in addition to an Ang II receptor blocking action, prevent an increase in Ang II level, and protect cardiovascular remodeling through an increase in cardiac nitric oxide production and endogenous Ang-(1-7) via over-expression of ACE2. 相似文献
4.
5.
6.
Abstract: Background: Few studies have examined in depth the labor progression of multiparas to determine if there is any additional impact of being parous beyond the first birth. The objective of this study was to determine the effect of parity on labor progression in contemporary obstetric practice. Methods: Our sample consisted of all low‐risk women who delivered a term, live‐born infant from January 2002 to March 2004 at a single institution in Delaware, United States (n = 5,589). The median duration of labor by each centimeter of cervical dilation was computed for parity = 0 (n = 2,645); parity = 1 (n = 1,839); parity = 2 (n = 750); and parity = 3 + (n = 355). Results: Multiparas had a significantly faster labor progression from 4 to 10 cm (293, 300, and 313 min, respectively, for parity = 1, parity = 2, and parity = 3 +), compared with nulliparas (383 min for parity = 0), as well as a shorter second stage of labor. However, no significant differences were found in duration of the active phase or the second stage of labor among multiparas. Conclusions: Additional childbearing appears to have no effect of on the progression of labor among multiparous subgroups. The difference in duration of the active phase between nulliparas and multiparas is substantially smaller in a contemporary population. (BIRTH 33:1 March 2006) 相似文献
7.
本实验制作不同程度心肌缺血的动物模型,以声处理5%人血白蛋白为超声造影剂进行心肌灌注造影,探讨MCE时间-强度曲线各指标与心肌缺血程度间的关系。结果表明:心肌显影的峰值强度和曲线下面积均与缺血程度呈显著负相关(相关系数分别为r=-0.98,P值<0.005;r=-0.94,P值<0.05),且能区分轻度、中度和重度三种程度的心肌缺血;而三项时间指标与心肌缺血程度间未发现显著性差异。本实验的初步结果表明,MCE是一项活体评估局部心肌血流灌注的有效方法。 相似文献
8.
目的:了解腮腺非霍奇金淋巴瘤与舍格伦综合征的临床及发病机制的相关性,正确诊断和治疗舍格伦综合征,尽早明确有无恶性变。方法:对142例口腔颌面部的非霍奇金淋巴瘤中21例发生在腮腺的非霍奇金淋巴瘤,及3例从合格伦综合征演变成淋巴瘤的病例进行分析。结果:21例腮腺区非霍奇金淋巴瘤的局部表现主要为肿块、反复肿胀,与类肿瘤型舍格伦综合征的一般特征和腮腺表现有相关性,其中3例腮腺淋巴瘤患者有明确的舍格伦综合征病史。结论:舍格伦综合征与腮腺非霍奇金淋巴瘤的发生发展,以及临床表现有相关性,部分类肿瘤型舍格伦综合征可演变为淋巴瘤,临床表现和免疫学改变可早期判断舍格伦综合征有无恶性变。 相似文献
9.
目的探索以虚拟现实技术为基础的枢椎椎弓根螺钉置人方法。方法选取8具成人颅一颈椎标本,采用改良四柱式定位框架固定于枕颈,使颅-颈-肩形成统一刚体,保持空间位置恒定,CT薄层扫描获取枢椎三维定位信息,采用Aero—Tech立体定向手术规划系统三维建模,设计安全、可视化、个体化的虚拟置钉路径,反复虚拟演示验证钉道安全后,导向弓把持下置人导向钢针,复查CT评价置钉的准确性。结果16个枢椎椎弓根置钉过程中,方向出现偏差(横突孔突破)1个,失败率为6.25%。结论目标椎弓根的容积三维重建、置钉路径可视化设计和虚拟演示,使操作过程简单、直观而精确,不需要线形和角性参数的测量;加上导向抓持装置提供的稳定性,使该技术具有很好的临床应用前景。 相似文献
10.
神经外科麻醉对体感诱发电位的影响 总被引:1,自引:0,他引:1
目的探讨神经外科手术麻醉对体感诱发电位(SEP)的影响,以期为麻醉和手术处理提供依据。方法随机抽取我科17例全麻手术病人,分成颅内疾病手术组(A组)与脊柱、脊髓疾病手术组(B组),于术前、麻醉(诱导完成)、术始、术中、术毕和术后6个时程连续监测SEP的潜伏期、波幅及波形并记录。结果麻醉后SEP潜伏期延长5.96%,波幅下降24.00%,未出现波形消失的情况。结论麻醉抑制SEP,表现为潜伏期延长和波幅下降,但未出现波形消失的情况。 相似文献